GlaxoSmithKline Research and Development Limited have notified the European Medicines Agency of its decision to withdraw its marketing authorisation application for casopitant mesilate (Zunrisa™) tablets.

Zunrisa was expected to be used in the prevention of post-operative nausea and vomiting and chemotherapy-induced nausea and vomiting. The withdrawal was based on the company’s assessment that further safety data would be required to support the registration of casopitant on a worldwide basis and that it would take considerable time to produce these data.